Polyclonal antibody preparation that depletes and suppresses T lymphocytes to reduce autoimmune marrow destruction.
Polyclonal anti-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and depletes/suppresses T lymphocytes via complement-dependent cytolysis and Fc-mediated clearance, reducing autoreactive T‑cell–mediated marrow destruction.
NO
INDIRECT
ALG binds multiple T‑cell surface antigens and depletes T cells via complement-mediated lysis and Fc-mediated clearance; it does not target HLA class I (e.g., HLA‑A) for killing.
Polyclonal antibody preparation that depletes and suppresses T lymphocytes to reduce autoimmune marrow destruction.
Polyclonal anti-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and depletes/suppresses T lymphocytes via complement-dependent cytolysis and Fc-mediated clearance, reducing autoreactive T‑cell–mediated marrow destruction.
YES
DIRECT
Polyclonal antibodies bind T‑cell surface antigens (including CD62L) and trigger complement-dependent lysis and Fc receptor–mediated ADCC/phagocytic clearance of the bound T cells.
Autologous HER2 (ERBB2)-targeted CAR T cells engineered with a hypoxia-stimulated CAR expression system to upregulate CAR under low oxygen, enhancing persistence and tumor killing in hypoxic solid tumors.
Autologous T cells engineered to express a HER2-specific chimeric antigen receptor whose expression is driven by a hypoxia-inducible system. In hypoxic tumor microenvironments, CAR expression increases, enabling targeted recognition and killing of HER2-positive tumor cells via T-cell activation, cytokine release, and cytotoxicity; hypoxia-regulated expression enhances T-cell persistence/expansion in solid tumors and may reduce off-tumor activity in normoxia.
YES
DIRECT
HER2-targeted CAR T cells (upregulated in hypoxia) recognize HER2 on tumor cells, form an immune synapse, and kill via T‑cell cytotoxic pathways (perforin/granzyme release and Fas/FasL signaling).
Autologous T lymphocytes genetically engineered to express a chimeric antigen receptor targeting carcinoembryonic antigen (CEA) for MHC-independent recognition and killing of CEA-positive tumor cells.
Autologous T cells are engineered to express a chimeric antigen receptor with an anti-CEA scFv, enabling MHC-independent recognition of CEA-positive tumor cells and inducing T-cell activation, expansion, cytokine release, and cytotoxic killing via perforin/granzyme pathways.
YES
DIRECT
CEA-targeted CAR-T cells bind CEA on tumor cells, become activated, and kill targets via perforin/granzyme-mediated cytolysis (with T cell effector mechanisms).
A humanized anti-TROP2 IgG1 antibody-drug conjugate that, after binding TROP2 on tumor cells and internalization, releases a membrane-permeable topoisomerase I inhibitor (DXd) via a cleavable linker to induce DNA damage, replication stress, and tumor cell death with a bystander effect.
Humanized anti-TROP2 IgG1 antibody-drug conjugate; after binding TROP2 and internalization, a cleavable linker releases the DXd topoisomerase I inhibitor payload, inducing DNA damage and replication stress to kill tumor cells, with a membrane-permeable bystander effect.
YES
DIRECT
The anti-TROP2 ADC binds TROP2, is internalized, and a cleavable linker releases the DXd topoisomerase I inhibitor inside the cell, causing DNA damage and replication stress that kills the target cell; the payload can also cause bystander killing.